Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.